{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:16:18Z","timestamp":1792718178770,"version":"4.5.0"},"reference-count":42,"publisher":"American Association for Cancer Research (AACR)","issue":"23","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The JAK2V617F mutation is present in almost all patients with polycythemia vera (PV), large proportions of patients with essential thrombocythemia and idiopathic myelofibrosis, and less frequently in atypical myeloproliferative disorders (MPD). We show that transplantation of JAK2V617F-transduced bone marrow into BALB\/c mice induces MPD reminiscent of human PV, characterized by erythrocytosis, granulocytosis, extramedullary hematopoiesis, and bone marrow fibrosis, but not thrombocytosis. Fluorescence-activated cell sorting of bone marrow and spleen showed proportional expansion of common myeloid progenitors, granulocyte-monocyte and megakaryocyte-erythrocyte progenitors. Megakaryocyte and late erythroid progenitors were dramatically increased, with only modest expansion of early erythroid progenitors. Erythropoietin (Epo) receptor expression was reduced on early, but normal on late erythroblasts. Serum levels of Epo and granulocyte colony-stimulating factor, but not granulocyte macrophage colony-stimulating factor, were reduced, whereas tumor necrosis factor-\u03b1 was increased, possibly exerting a negative effect on JAK2V617F-negative hematopoiesis. These data suggest that erythrocytosis and granulocytosis in JAK2V617F mice are the net result of a complex interplay between cell intrinsic and extrinsic factors. There were no thromboembolic events and no animals succumbed to their disease, implicating additional factors in the manifestation of human disease. The disease was not transplantable and prolonged observation showed normalization of blood counts in most JAK2V617F mice, suggesting that the mutation may not confer self-renewal capacity. (Cancer Res 2006; 66(23): 11156-65)<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-2210","type":"journal-article","created":{"date-parts":[[2006,12,4]],"date-time":"2006-12-04T12:52:48Z","timestamp":1165236768000},"page":"11156-11165","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":178,"title":["Characterization of Murine JAK2V617F-Positive Myeloproliferative Disease"],"prefix":"10.1158","volume":"66","author":[{"given":"Thomas G.P.","family":"Bumm","sequence":"first","affiliation":[{"name":"1Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin","family":"Elsea","sequence":"additional","affiliation":[{"name":"1Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute;"},{"name":"3Oregon Health and Science University School of Nursing;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie S.","family":"Corbin","sequence":"additional","affiliation":[{"name":"1Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute;"},{"name":"4Howard Hughes Medical Institute, Portland, Oregon; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Loriaux","sequence":"additional","affiliation":[{"name":"1Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute;"},{"name":"2Department of Pathology, Oregon Health and Science University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sherbenou","sequence":"additional","affiliation":[{"name":"1Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wood","sequence":"additional","affiliation":[{"name":"1Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute;"},{"name":"3Oregon Health and Science University School of Nursing;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Deininger","sequence":"additional","affiliation":[{"name":"2Department of Pathology, Oregon Health and Science University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Silver","sequence":"additional","affiliation":[{"name":"5Cornell University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[{"name":"1Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute;"},{"name":"4Howard Hughes Medical Institute, Portland, Oregon; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.N.","family":"Deininger","sequence":"additional","affiliation":[{"name":"1Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2006,12,4]]},"reference":[{"key":"2022061622152720500_B1","doi-asserted-by":"crossref","unstructured":"Dameshek W. Some speculations on the myeloproliferative syndromes. Blood\u20081951; 6: 372\u20135.","DOI":"10.1182\/blood.V6.4.372.372"},{"key":"2022061622152720500_B2","unstructured":"Vardiman JW, Pierre R, Thiele J, Imbert M, Brunning RD, Flandrin G. Chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 15\u201359."},{"key":"2022061622152720500_B3","doi-asserted-by":"crossref","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science\u20081990; 247: 1079\u201382.","DOI":"10.1126\/science.2408149"},{"key":"2022061622152720500_B4","doi-asserted-by":"crossref","unstructured":"Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med\u20082003; 348: 1201\u201314.","DOI":"10.1056\/NEJMoa025217"},{"key":"2022061622152720500_B5","doi-asserted-by":"crossref","unstructured":"James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature\u20082005; 434: 1144\u20138.","DOI":"10.1038\/nature03546"},{"key":"2022061622152720500_B6","doi-asserted-by":"crossref","unstructured":"Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet\u20082005; 365: 1054\u201361.","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"2022061622152720500_B7","doi-asserted-by":"crossref","unstructured":"Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell\u20082005; 7: 387\u201397.","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"2022061622152720500_B8","doi-asserted-by":"crossref","unstructured":"Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med\u20082005; 352: 1779\u201390.","DOI":"10.1056\/NEJMoa051113"},{"key":"2022061622152720500_B9","doi-asserted-by":"crossref","unstructured":"Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood\u20082005; 106: 2162\u20138.","DOI":"10.1182\/blood-2005-03-1320"},{"key":"2022061622152720500_B10","doi-asserted-by":"crossref","unstructured":"Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and the myelodysplastic syndrome. Blood\u20082005; 106: 1207\u20139.","DOI":"10.1182\/blood-2005-03-1183"},{"key":"2022061622152720500_B11","doi-asserted-by":"crossref","unstructured":"Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood\u20082005; 106: 3377\u20139.","DOI":"10.1182\/blood-2005-05-1898"},{"key":"2022061622152720500_B12","doi-asserted-by":"crossref","unstructured":"Lindauer K, Loerting T, Liedl KR, Kroemer RT. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng\u20082001; 14: 27\u201337.","DOI":"10.1093\/protein\/14.1.27"},{"key":"2022061622152720500_B13","doi-asserted-by":"crossref","unstructured":"Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell\u20081998; 93: 385\u201395.","DOI":"10.1016\/S0092-8674(00)81167-8"},{"key":"2022061622152720500_B14","doi-asserted-by":"crossref","unstructured":"Neubauer H, Cumano A, Muller M, et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell\u20081998; 93: 397\u2013409.","DOI":"10.1016\/S0092-8674(00)81168-X"},{"key":"2022061622152720500_B15","doi-asserted-by":"crossref","unstructured":"Dai CH, Krantz SB, Dessypris EN, et al. Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood\u20081992; 80: 891\u20139.","DOI":"10.1182\/blood.V80.4.891.891"},{"key":"2022061622152720500_B16","doi-asserted-by":"crossref","unstructured":"Casadevall N, Vainchenker W, Lacombe C, et al. Erythroid progenitors in polycythemia vera: demonstration of their hypersensitivity to erythropoietin using serum free cultures. Blood\u20081982; 59: 447\u201351.","DOI":"10.1182\/blood.V59.2.447.447"},{"key":"2022061622152720500_B17","unstructured":"James H, Mills K, Gibson I. Investigating and improving the specificity of ribozymes directed against the bcr-abl translocation. Leukemia\u20081996; 10: 1676."},{"key":"2022061622152720500_B18","doi-asserted-by":"crossref","unstructured":"Wernig G, Mercher T, Okabe R, et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood\u20082006; 107: 4274\u201381.","DOI":"10.1182\/blood-2005-12-4824"},{"key":"2022061622152720500_B19","doi-asserted-by":"crossref","unstructured":"Lacout C, Pisani DF, Tulliez M, et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood\u20082006; 108: 1652\u201360.","DOI":"10.1182\/blood-2006-02-002030"},{"key":"2022061622152720500_B20","doi-asserted-by":"crossref","unstructured":"Ghaffari S, Kitidis C, Zhao W, et al. AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation. Blood\u20082006; 107: 1888\u201391.","DOI":"10.1182\/blood-2005-06-2304"},{"key":"2022061622152720500_B21","doi-asserted-by":"crossref","unstructured":"Spivak JL, Barosi G, Tognoni G, et al. Chronic myeloproliferative disorders. Hematology Am Soc Hematol Educ Program 2003;200\u201324.","DOI":"10.1182\/asheducation-2003.1.200"},{"key":"2022061622152720500_B22","doi-asserted-by":"crossref","unstructured":"Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet\u20082005; 366: 1945\u201353.","DOI":"10.1016\/S0140-6736(05)67785-9"},{"key":"2022061622152720500_B23","doi-asserted-by":"crossref","unstructured":"Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol\u20082006; 132: 244\u20135.","DOI":"10.1111\/j.1365-2141.2005.05858.x"},{"key":"2022061622152720500_B24","doi-asserted-by":"crossref","unstructured":"Bunting KD, Yu WM, Bradley HL, et al. Increased numbers of committed myeloid progenitors but not primitive hematopoietic stem\/progenitors in mice lacking STAT6 expression. J Leukoc Biol\u20082004; 76: 484\u201390.","DOI":"10.1189\/jlb.0903440"},{"key":"2022061622152720500_B25","doi-asserted-by":"crossref","unstructured":"Armstrong L, Stojkovic M, Dimmick I, et al. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells\u20082004; 22: 1142\u201351.","DOI":"10.1634\/stemcells.2004-0170"},{"key":"2022061622152720500_B26","doi-asserted-by":"crossref","unstructured":"Bozzini CE, Barrio Rendo ME, Devoto FC, Epper CE. Studies on medullary and extramedullary erythropoiesis in the adult mouse. Am J Physiol\u20081970; 219: 724\u20138.","DOI":"10.1152\/ajplegacy.1970.219.3.724"},{"key":"2022061622152720500_B27","doi-asserted-by":"crossref","unstructured":"Huntly BJP, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer\u20082005; 5: 311\u201321.","DOI":"10.1038\/nrc1592"},{"key":"2022061622152720500_B28","doi-asserted-by":"crossref","unstructured":"Curtis DJ, Hall MA, Van Stekelenburg LJ, et al. SCL is required for normal function of short-term repopulating hematopoietic stem cells. Blood\u20082004; 103: 3342\u20138.","DOI":"10.1182\/blood-2003-09-3202"},{"key":"2022061622152720500_B29","doi-asserted-by":"crossref","unstructured":"Jamieson CH, Gotlib J, Durocher JA, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A\u20082006; 103: 6224\u20139.","DOI":"10.1073\/pnas.0601462103"},{"key":"2022061622152720500_B30","doi-asserted-by":"crossref","unstructured":"Suzuki N, Suwabe N, Ohneda O, et al. Identification and characterization of 2 types of erythroid progenitors that express GATA-1 at distinct levels. Blood\u20082003; 102: 3575\u201383.","DOI":"10.1182\/blood-2003-04-1154"},{"key":"2022061622152720500_B31","doi-asserted-by":"crossref","unstructured":"Nakorn TN, Miyamoto T, Weissman IL. Characterization of mouse clonogenic megakaryocyte progenitors. Proc Natl Acad Sci U S A\u20082003; 100: 205\u201310.","DOI":"10.1073\/pnas.262655099"},{"key":"2022061622152720500_B32","doi-asserted-by":"crossref","unstructured":"Panteli KE, Hatzimichael EC, Bouranta PK, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6, and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol\u20082005; 130: 709\u201315.","DOI":"10.1111\/j.1365-2141.2005.05674.x"},{"key":"2022061622152720500_B33","doi-asserted-by":"crossref","unstructured":"Zeuner A, Pedini F, Signore M, et al. Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. Blood\u20082006; 107: 3495\u2013502.","DOI":"10.1182\/blood-2005-07-3037"},{"key":"2022061622152720500_B34","doi-asserted-by":"crossref","unstructured":"Lu X, Levine R, Tong W, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A\u20082005; 102: 18962\u20137.","DOI":"10.1073\/pnas.0509714102"},{"key":"2022061622152720500_B35","doi-asserted-by":"crossref","unstructured":"Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol\u20082004; 32: 179\u201387.","DOI":"10.1016\/j.exphem.2003.11.003"},{"key":"2022061622152720500_B36","doi-asserted-by":"crossref","unstructured":"Xiao W, Koizumi K, Nishio M, et al. Tumor necrosis factor-\u03b1 inhibits generation of glycophorin A+ cells by CD34+ cells. Exp Hematol\u20082002; 30: 1238\u201347.","DOI":"10.1016\/S0301-472X(02)00930-X"},{"key":"2022061622152720500_B37","doi-asserted-by":"crossref","unstructured":"Jacobs-Helber SM, Roh KH, Bailey D, et al. Tumor necrosis factor-\u03b1 expressed constitutively in erythroid cells or induced by erythropoietin has negative and stimulatory roles in normal erythropoiesis and erythroleukemia. Blood\u20082003; 101: 524\u201331.","DOI":"10.1182\/blood-2001-11-0084"},{"key":"2022061622152720500_B38","doi-asserted-by":"crossref","unstructured":"Battegay EJ, Raines EW, Colbert T, Ross R. TNF-\u03b1 stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression. J Immunol\u20081995; 154: 6040\u20137.","DOI":"10.4049\/jimmunol.154.11.6040"},{"key":"2022061622152720500_B39","unstructured":"Smith BD, La Celle PL. Blood viscosity and thrombosis: clinical considerations. Prog Hemost Thromb\u20081982; 6: 179\u2013201."},{"key":"2022061622152720500_B40","doi-asserted-by":"crossref","unstructured":"Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood\u20082000; 96: 4261\u20136.","DOI":"10.1182\/blood.V96.13.4261"},{"key":"2022061622152720500_B41","doi-asserted-by":"crossref","unstructured":"Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr\/abl-transduced bone marrow. Blood\u20081998; 92: 3780\u201392.","DOI":"10.1182\/blood.V92.10.3780"},{"key":"2022061622152720500_B42","doi-asserted-by":"crossref","unstructured":"Huntly BJ, Shigematsu H, Deguchi K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell\u20082004; 6: 587\u201396.","DOI":"10.1016\/j.ccr.2004.10.015"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/23\/11156\/2556478\/11156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/23\/11156\/2556478\/11156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T17:51:58Z","timestamp":1683654718000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/66\/23\/11156\/526473\/Characterization-of-Murine-JAK2V617F-Positive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,1]]},"references-count":42,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2006,12,4]]},"published-print":{"date-parts":[[2006,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-2210","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22366593.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366602","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366587.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366584.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366581.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366599.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366581","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366590","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366602.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366599","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366590.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366587","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366584","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366593","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6495210.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6495210","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12,1]]}}}